ClinicalTrials.gg
Active, not recruitingNCT06367166Updated Jul 23, 2025

Effects of Bioflavanoids on Vascular Wall Remodeling in Patients With Varicose Veins

An interventional study of "Venarus®" (diosmin and hesperidin) and Endovenous laser ablation (EVLA) with miniphlebectomy in Varicose Veins of Lower Limb, Varix and Vascular Diseases, sponsored by Ryazan State Medical University. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by Ryazan State Medical University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as active, not recruiting.
  • Registered 6 months after the study started (first participant enrolled Apr 2023, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The study is aimed at assessing the dynamics of changes in biochemical markers of venous wall remodeling (type 1 plasminogen activation inhibitor (PAI-1), fibronectin (fibronectin, FN), vimentin (vimentin, VM), von Willebrand factor (vWF), PECAM-1 (CD31) ) in patients with C2s-C3s varicose veins compared with healthy volunteers while taking Venarus® (diosmin in combination with hesperidin).

Read the detailed description

The study will include 80 patients with varicose veins of the lower extremities, CEAP (CEAP classification stands for Clinical (C), Etiological (E), Anatomical (A), and Pathophysiological (P)) clinical class C2s-C3s and 20 healthy volunteers of similar age, gender, and ethnicity (100 patients altogether). The study participants will be divided into five groups: Group A: 20 patients with varicose veins who will be treated conservatively - receive the drug "Venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months; Group B: 20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with venoactive drugs and will not undergo invasive treatment; Group C: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; Group D: 20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), after which no venoactive drugs will be prescribed. Group E: 20 healthy volunteers without clinical and ultrasound signs of varicose veins.

All subjects in groups A, B, C, and D will receive elastic compression.

02

Conditions studied

  • Varicose Veins of Lower Limb
  • Varix
  • Vascular Diseases
  • Leg Edema

Keywords

  • bioflavonoids
  • venous remodeling
  • varicose veins
03

In context

Varicose Veins

226 studies on the registry are indexed under Varicose Veins; 30 are open to participants now.

This study's enrollment of 100 is close to the median of 101 across 154 interventional studies indexed under Varicose Veins.

Browse Varicose Veins studies →

Lead sponsor

Ryazan State Medical University is the lead sponsor of 21 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study will include men or women over 18 years of age with varicose disease of the lower extremities C2-C3 according to the CEAP classification, confirmed by ultrasound duplex scanning of the veins of the lower extremities

Exclusion criteria

Exclusion Criteria:

  • the presence of neoplasms, previous operations on the vessels of the lower extremities, deep vein thrombosis, severe concomitant diseases, including infectious ones, pregnancy, lactation
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    А- Varicose vein patients with Conservative treatment with a venoactive drug

    20 patients with varicose veins who will be treated conservatively - receive the drug "Venarus®" (diosmin in combination with hesperidin) at a dosage of 1000 mg once daily for 6 months along with elastic compression

    Drug: "Venarus®" (diosmin and hesperidin) · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

  • Experimental
    B- Varicose veins patients without invasive treatment or a venoactive drug

    20 patients with varicose veins C2s-C3s who are not prescribed conservative therapy with a venoactive drug and will not undergo invasive treatment; the patients will receive elastic compression

    Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

  • Experimental
    C- Varicose veins patients who will undergo EVLA and conservative treatment with a venoactive drug

    20 patients with varicose veins who will undergo invasive treatment (endovenous laser ablation with miniphlebectomy), followed by Venarus at a dosage of 1000 mg once daily for 6 months; the patients will also receive elastic compression

    Drug: "Venarus®" (diosmin and hesperidin) · Procedure: Endovenous laser ablation (EVLA) with miniphlebectomy · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

  • Experimental
    D- Varicose veins patients who will undergo EVLA

    20 patients with varicose veins patients who will undergo invasive treatment (EVLK with miniphlebectomy), after which no venoactive drugs will be prescribed; the patients will also receive elastic compression

    Procedure: Endovenous laser ablation (EVLA) with miniphlebectomy · Other: Elastic compression · Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

  • Experimental
    E-healthy volunteers

    20 healthy volunteers without clinical and ultrasound signs of varicose veins receiving no treatment

    Other: Evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

Interventions

  • Drug"Venarus®" (diosmin and hesperidin)

    "Venarus®" (diosmin and hesperidin) at a dosage of 1000 mg once daily for 6 months

    Also known as: BIOFLAVANOIDS

  • ProcedureEndovenous laser ablation (EVLA) with miniphlebectomy

    Endovenous laser ablation will be performed under local and tumescent anesthesia, laser wavelength 1470nm.

  • OtherElastic compression

    All subject with varicose veins enrolled in the study will receive class 2 elastic compression (elastic stockings) after enrollment

  • OtherEvaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), venous symptoms and severity scores

    The patients and healthy volunteers will undergo evaluation of biomarkers of venous wall remodeling (fibronectin, PAI-1, vimentin, vWF, CD31), Venous clinical severity (VCS) score, Visual Analog Scale (VAS) score and 20 item-ChronIc Venous dIsease quality-of-life Questionnaire (CIVIQ-20) at baseline, and 2, 3, and 6 months after enrollment

06

What researchers measure

Primary outcomes

  1. changes in biomarkers of venous wall remodeling

    Changes in biomarkers of venous wall remodeling including vimentin, fibronectin, PAI-1, vWF, CD31

    Time frame: At baseline, and at 2, 3 and 6 months after the start of treatment

  2. Changes in biomarkers expression in venous wall

    Changes in expression of biomarkers of venous wall remodeling (vimentin, fibronectin, PAI-1, vWF, CD31) as assessed with Western blot techniques using the dilated veins harvested during miniphlebectomy

    Time frame: 6 months

07

Study locations

1 site
  • RyazanSMU
    Ryazan, Russia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Apr 2026, 36 months after the start.

Of 63 non-industry interventional studies with no phase under Varicose Veins, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 36 months is above that.

Counting every sponsor, half of 73 studies reached it within 22 months; a quarter within 11 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Apr 16, 2024
StartActual
Apr 1, 2023
Primary completionEst.
Apr 1, 2026
CompletionEst.
May 1, 2026
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06367166
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
Apr 16, 2024
Start date
Apr 1, 2023
Primary completion
Apr 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Jul 23, 2025

Study contacts

Igor Suchkov
principal investigator · RyazSMU

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion